The Marked Chart Wire · Business
Pfizer Obesity
Blackstone to fund up to $1.5 billion for Pfizer obesity drug
Blackstone Life Sciences will provide up to $1.5 billion to Pfizer through 2028 to support its obesity program. Pfizer retains full operational control of the berobenatide initiative.
Part of a series: Pfizer clears FDA hurdle, beats earnings, and secures obesity funding
